The Clinical Research Management (CRM) Shared Resource provides over-sight and training services for CRM personnel, maintains all protocols in a central location, advises investigators on eligibility for centralized patient registration, disseminates appropriate information for protocol development, supports centralized data management (except for data entry for individual projects) and provides quality assurance oversight of Clinical Research Specialists and Data Managers involved in the conduct of clinical trials supported by the Oregon Cancer Center. Two related components, described in subsequent sections, detail this overall activity: Protocol Specific Research Support and the Clinical Trial Scientific Review and Monitoring System. Protocol Specific Research Support is used to support innovative and translational investigator initiated Pilot/Phase I and small Phase II institutional protocols which have been reviewed and approved by the Clinical Research Review Committee (CRRC) with high priority. The Protocol Review and Monitoring System, Section 9.9 of the CCSG, is the mechanism by which proposed projects are retrieved and ongoing Cancer Center supported clinical research projects are monitored. The impetus for providing centralized services through the CRM is to ensure high quality data management and conduct for clinical research, cost effectiveness, elimination of duplicative efforts, and to provide and mechanism for fostering collaboration among investigators interested in addressing the cancer problem through innovative institutional clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-04
Application #
6323300
Study Section
Project Start
2000-06-19
Project End
2001-05-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Showing the most recent 10 out of 277 publications